Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc


Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc

Big drugmaker. High dividend yield. Promising new products. 

All three apply to AbbVie Inc. (NYSE: ABBV). They also all apply to GlaxoSmithKline plc (NYSE: GSK). But while AbbVie stock has achieved solid gains so far in 2017, GlaxoSmithKline's share price isn't very far above where it started out the year. Past performance doesn't necessarily make one stock better than the other, though. Which of these big pharma stocks is the smarter pick for investors now? Here's how AbbVie and GlaxoSmithKline compare.

Image source: Getty Images.

Continue reading


Source: Fool.com

GSK plc ADR Stock

€40.60
-0.990%
The price for the GSK plc ADR stock decreased slightly today. Compared to yesterday there is a change of -€0.400 (-0.990%).

Like: 0
GSK
Share

Comments